Ubs Group Ag Rapt Therapeutics, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 28,846 shares of RAPT stock, worth $49,903. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,846

Previous 28,588 0.9%

Holding current value

$49,903

Previous $87,000 34.48%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.76 - $3.75 $454 - $967	258 Added 0.9%	28,846 $57,000
Q2 2024 Aug 13, 2024	SELL	$2.89 - $9.38 $77,969 - $253,063	-26,979 Reduced 48.55%	28,588 $87,000
Q1 2024 May 13, 2024	SELL	$6.87 - $26.45 $236,623 - $911,017	-34,443 Reduced 38.27%	55,567 $498,000
Q4 2023 Feb 09, 2024	BUY	$11.28 - $25.46 $628,363 - $1.42 Million	55,706 Added 162.39%	90,010 $2.24 Million
Q3 2023 Nov 09, 2023	SELL	$16.34 - $24.66 $213,988 - $322,947	-13,096 Reduced 27.63%	34,304 $570,000
Q2 2023 Aug 11, 2023	SELL	$16.06 - $21.61 $22,564 - $30,362	-1,405 Reduced 2.88%	47,400 $886,000
Q1 2023 May 12, 2023	SELL	$17.19 - $30.8 $875,641 - $1.57 Million	-50,939 Reduced 51.07%	48,805 $895,000
Q4 2022 Feb 08, 2023	BUY	$16.28 - $24.6 $1.44 Million - $2.17 Million	88,229 Added 766.21%	99,744 $1.97 Million
Q3 2022 Nov 10, 2022	BUY	$17.96 - $30.46 $158,479 - $268,779	8,824 Added 327.91%	11,515 $277,000
Q2 2022 Aug 10, 2022	SELL	$10.26 - $23.59 $433,700 - $997,172	-42,271 Reduced 94.01%	2,691 $49,000
Q1 2022 May 16, 2022	SELL	$17.02 - $40.22 $564,230 - $1.33 Million	-33,151 Reduced 42.44%	44,962 $989,000
Q4 2021 Feb 14, 2022	BUY	$29.5 - $39.5 $2.12 Million - $2.84 Million	71,883 Added 1153.82%	78,113 $2.87 Million
Q3 2021 Nov 15, 2021	BUY	$29.86 - $39.47 $1,552 - $2,052	52 Added 0.84%	6,230 $193,000
Q2 2021 Aug 13, 2021	SELL	$17.99 - $40.02 $50,336 - $111,975	-2,798 Reduced 31.17%	6,178 $196,000
Q1 2021 May 12, 2021	BUY	$16.0 - $24.46 $14,000 - $21,402	875 Added 10.8%	8,976 $199,000
Q4 2020 Feb 11, 2021	SELL	$15.89 - $40.87 $179,811 - $462,484	-11,316 Reduced 58.28%	8,101 $160,000
Q3 2020 Nov 12, 2020	BUY	$21.6 - $37.5 $83,224 - $144,487	3,853 Added 24.76%	19,417 $626,000
Q2 2020 Jul 31, 2020	BUY	$14.16 - $32.85 $197,900 - $459,111	13,976 Added 880.1%	15,564 $451,000
Q1 2020 May 01, 2020	SELL	$11.86 - $48.86 $15,963 - $65,765	-1,346 Reduced 45.88%	1,588 $34,000
Q4 2019 Feb 14, 2020	BUY	$12.3 - $30.78 $36,088 - $90,308	2,934 New	2,934 $81,000

Others Institutions Holding RAPT

# of Institutions

104

Shares Held

27.1M

Call Options Held

26.7K

Put Options Held

2.4K

View Full List

About RAPT Therapeutics, Inc.

Ticker RAPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,656,600
Market Cap $51.3M
Description
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...

More about RAPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account